PET/CT Imaging in Prostate Cancer Patients
This video interview series features Neal Shore, MD, and Stephen Rowe, MD, PhD, who share their expert insights and perspectives on innovation in the imaging of patients with prostate cancer and the identification of metastases. Topics covered include recent advances in PSMA-directed imaging, the advantages of PET imaging, and the fusion of PET/CT or PET/MRI techniques. In addition, they also discuss the OSPREY and CONDOR clinical studies that led to the approval of PYLARIFY® (piflufolastat F 18) by the FDA in May 2021.
Dr Steven Rowe shares insights into the prostate cancer imaging landscape and the logistics involved with different radiotracers, with particular emphasis on PYLARIFY® (piflufolastat F 18). Read More ›
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients. Read More ›
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®. Read More ›
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent. Read More ›
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer. Read More ›
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging. Read More ›
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Read More ›
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18). Read More ›